Novo Nordisk acquires IP rights from Neose Technologies

Published: 18-Sep-2008
Media Research & Development

Novo Nordisk in Denmark, has signed an agreement to acquire intellectual property rights from Neose Technologies Inc. related to Neose\'s proprietary GlycoPEGylation technology.


Novo Nordisk in Denmark, has signed an agreement to acquire intellectual property rights from Neose Technologies Inc. related to Neose's proprietary GlycoPEGylation technology.

The acquired rights are currently subject to a license from Neose for Novo Nordisk's development of GlycoPEGylated recombinant blood clotting factors FVIIa, FVIII and FIX.

The transaction is in line with Novo Nordisk's strategy of expanding its presence within general haemophilia. The total acquisition cost amounts to approximately US$ 21m.

The agreement is subject to approval by the shareholders in Neose Technologies Inc.

GlycoPEGylation is a technology developed to enable selective addition of polyethylene glycol (PEG) to sugar chains whereby protein half-life can be extended and customised.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.

  • Companies:
  • Novo Nordisk Pharmatech
See more

You may also like

Regulatory

Anti-IL-21 monoclonal antibody licensed by Almirall

Read more
NN-8828, the IL-21 blocker, is exclusively owned by Almirall and will be used to treat immune inflammatory dermatological diseases

Trending Articles

  1. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  2. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  3. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D
  4. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  5. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Regulatory

Anti-IL-21 monoclonal antibody licensed by Almirall

NN-8828, the IL-21 blocker, is exclusively owned by Almirall and will be used to treat immune inflammatory dermatological diseases
Manufacturing

BioInnovation adds eight early-stage companies to acceleration programme

Lomo, Novozymes and Amalus are all among the eight countries selected by BII to join its acceleration programme for early-stage companies looking to strike out into the pharmaceutical industry
Manufacturing

Data shows insulin icodec meets additional endpoints in adults with type 2 diabetes in phase 3a trials

The results were shared at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA)
Research & Development

Novo Nordisk and MIT extend oral delivery tech collaboration

Since 2015, the industry-academia venture has explored alternatives to syringe and pen-based delivery of biologics
Research & Development

Novo Nordisk funds $27m global biomanufacturing programme

The five-year research and training project will be run as a collaborative effort between North Carolina State University and the Technical University of Denmark
Media

Bristol diabetes spin-out company acquired by Novo Nordisk

The global healthcare company has acquired all of the shares of the Bristol supramolecular chemistry company, of which total payments under the agreement could ultimately exceed $800 million
Media

GlobalData publishes analysis of top 25 global pharma companies

The data and analytics company has tracked the market cap performance of the top 25 pharma companies for the quarter ending 31 March, 2018 compared to 2017 revealing a number of interesting insights
Subscribe now